SPOTLIGHT: CuraGen sells Belinostat stake to TopoTarget

CuraGen Corporation has sold its stake in Belinostat to TopoTarget for $39 million upfront in a combination of cash and stock. TopoTarget will now take full control of the cancer drug's development. "CuraGen has been a good partner and helped us over a high risk period," said Dr. Peter Buhl Jensen, CEO of TopoTarget. CuraGen said the move allows it to focus on other clinical programs. Release

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.